← All trials
NCT04502602
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 24, 2020
- Primary completion
- May 31, 2024
- Completion date
- May 31, 2029
- First posted
- Aug 6, 2020
- Last posted
- Aug 26, 2020
- Enrollment
- 45
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Virginia Commonwealth UniversityLead sponsor
- Virginia Commonwealth UniversityOverall official - principal investigator
- GlaxoSmithKlineCollaborator
- Puma Biotechnology, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.